---
figid: PMC4026543__cjc-33-05-231-g002
figtitle: EPH receptors crosstalk with EMT-related signaling pathways
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4026543
filename: cjc-33-05-231-g002.jpg
figlink: /pmc/articles/PMC4026543/figure/cjc-33-05-231-g002/
number: F2
caption: EPH receptors initiate forward signaling to promote cancer progression via
  the MAPK signaling pathway in both ligand-dependent and ligand-independent manners.
  EPHRIN-mediated reverse signaling also contributes to tumorigenicity by inhibiting
  apoptosis. The Wnt/β-catenin signaling pathway promotes tumor progression by up-regulating
  EPHB4 and down-regulating EPHB2, whereas EPHB3 inhibits the Wnt signaling pathway.
  EPHA2 promotes EMT through the Wnt/β-catenin signaling pathway. CBP, cyclic AMP-responsive
  related binding protein; ECM, extracellular matrix; ERK, extracellular regulated
  protein kinase; NF-κβ, nuclear factor kappa-light-chain-enhancer of activated B
  cell; MAPK, mitogen-activated protein kinase; mTORC1, mammalian target of rapamycin
  (mTOR) complex 1; PI3K, phosphatidylinositol 3-kinase; Red P, phosphorylation; RTKs,
  receptor tyrosine kinases; TCF, T-cell factor.
papertitle: The role of EPH receptors in cancer-related epithelial-mesenchymal transition.
reftext: Rui-Xin Li, et al. Chin J Cancer. 2014 May;33(5):231-240.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9707518
figid_alias: PMC4026543__F2
figtype: Figure
redirect_from: /figures/PMC4026543__F2
ndex: a9b3b899-dec6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4026543__cjc-33-05-231-g002.html
  '@type': Dataset
  description: EPH receptors initiate forward signaling to promote cancer progression
    via the MAPK signaling pathway in both ligand-dependent and ligand-independent
    manners. EPHRIN-mediated reverse signaling also contributes to tumorigenicity
    by inhibiting apoptosis. The Wnt/β-catenin signaling pathway promotes tumor progression
    by up-regulating EPHB4 and down-regulating EPHB2, whereas EPHB3 inhibits the Wnt
    signaling pathway. EPHA2 promotes EMT through the Wnt/β-catenin signaling pathway.
    CBP, cyclic AMP-responsive related binding protein; ECM, extracellular matrix;
    ERK, extracellular regulated protein kinase; NF-κβ, nuclear factor kappa-light-chain-enhancer
    of activated B cell; MAPK, mitogen-activated protein kinase; mTORC1, mammalian
    target of rapamycin (mTOR) complex 1; PI3K, phosphatidylinositol 3-kinase; Red
    P, phosphorylation; RTKs, receptor tyrosine kinases; TCF, T-cell factor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EPHB3
  - EPHA2
  - EPHA1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - RAC1
  - RNASE1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - CTNNB1
  - NFKB1
  - RPTOR
  - HNF4A
  - ELK1
  - KCNH4
  - KCNH8
  - CREBBP
  - EIF4E
  - OPN1LW
  - PAG1
  - PCBP4
  - SNAI1
  - CDH1
  - FZR1
  - EPHB4
  - ITK
  - SLC22A3
  - Cancer
---
